Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease.

[1]  F. Johnson,et al.  Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. , 2019, Journal of Crohn's & colitis.

[3]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.

[4]  S. Targan,et al.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.

[5]  Frank I. Scott,et al.  Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  B. Behm,et al.  Nonadherence to Biologic Therapies in Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.

[7]  M. Murad,et al.  Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease , 2018, Alimentary pharmacology & therapeutics.

[8]  M. Regueiro,et al.  ACG Clinical Guideline: Management of Crohn’s Disease in Adults , 2018, The American Journal of Gastroenterology.

[9]  Frank I. Scott,et al.  Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. , 2018, Inflammatory bowel diseases.

[10]  Z. Zeng,et al.  Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease , 2017, Journal of Gastroenterology.

[11]  Frank I. Scott,et al.  The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  A. Bitton,et al.  DOP074 Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis , 2014 .

[13]  J. Lewis,et al.  Impact of JC Virus Antibody Testing in Patients with Crohn's Disease with Loss of Response to Infliximab: A Markov Model , 2013, Inflammatory bowel diseases.

[14]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[15]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[16]  L. Peyrin-Biroulet,et al.  Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review , 2013, Inflammatory bowel diseases.

[17]  B. Strober,et al.  Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up , 2013, The British journal of dermatology.

[18]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[19]  M. Turner,et al.  Safety of Infliximab and Other Crohn's Disease Therapies: Treat™ Registry Data With a Mean of 5 Years of Follow-up , 2011 .

[20]  K. Simon,et al.  Anti‐JC virus antibodies: Implications for PML Risk Stratification , 2010, Annals of neurology.

[21]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[22]  Thomas R Ten Have,et al.  Determinants of the optimal first‐line therapy for follicular lymphoma: A decision analysis , 2010, American journal of hematology.

[23]  L. Peyrin-Biroulet,et al.  The Natural History of Adult Crohn's Disease in Population-Based Cohorts , 2010, The American Journal of Gastroenterology.

[24]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[25]  M. Weinstein,et al.  QALYs: the basics. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[27]  P. Rutgeerts,et al.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.

[28]  D. Margolis,et al.  Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.

[29]  Murray Krahn,et al.  The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  P. Rutgeerts,et al.  JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? , 2008, Gut.

[31]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[32]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[33]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[34]  J. Berger,et al.  Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. , 2005, The New England journal of medicine.

[35]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[36]  J. Rubenstein,et al.  Infliximab Decreases Resource Use Among Patients With Crohn's Disease , 2002, Journal of clinical gastroenterology.

[37]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[38]  J. Schwartz,et al.  Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. , 2000, Gastroenterology.

[39]  B. Feagan,et al.  An Evaluation of Utility Measurement in Crohn's Disease , 1997, Inflammatory bowel diseases.

[40]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[41]  P. Rutgeerts,et al.  IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. , 2019, Journal of Crohn's & colitis.

[42]  B. Sands,et al.  Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.

[43]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[44]  A. Tosteson,et al.  Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[45]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[46]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[47]  R. N. Anderson,et al.  National Vital Statistics Reports , 1999 .